|
RNAi Whole genome scanning Stem Cells Enhanced delivery . along with increased complexity and integration Genomics Gene Cell Proteomics System Metabolomics Drug Toxicogenomics.
Effects and abuse potential . Utilization between 10 22 2004 and10 21 2005 was 474 claims for this agent with a cost of over 5, 000. The number of claims has not significantly increased since the recategorization of megestrol acetate suspension. Conclusion: There is no evidence to support inappropriate use of this agent. Recommendation: No intervention is recommended at this time but continued monitoring of Oxandrin is advised Lyrica Utilization: Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy and post herpetic neuralgia. It is also indicated as adjunctive therapy for adult patients with partial onset seizures. Dennis continued with dosing, administration and mechanism of action reviews. Utilization: Dennis presented a chart to the Board and continued with the conclusions of the study. 1. 10 beneficiaries or 32% have a diagnosis of diabetes 2. Of the 10 beneficiaries, only 4 have claims for anti-diabetic medications 3. 9 beneficiaries or 29% have at least one recent claim for another anticonvulsant medication 4. None of the recipients who have received Lyrica have a diagnosis of herpes zoster or post herpetic neuralgia. Recommendation: Although this new medication has seen limited utilization to this point, this analysis indicates that a significant number of patients who have received Lyrica do not have a diagnosis for which it is indicated. It is recommended that this agent be monitored over the coming months to evaluate utilization trends. Motion: Dr. Montgomery made a motion to accept the recommendations as indicated by HID. Dr. Runnels seconded the motion. All voted in favor of the motion. Black Box Warnings: Avinza: Audience: pain specialists, other healthcare professionals and consumers Posted 11 03 2005 Ligand pharmaceuticals and FDA notified healthcare professionals of revisions to BOXED WARNING, WARNINGS, PRECAUTIONS, and CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION sections of the prescribing information to highlight and strengthen the warning that patients should not consume alcohol while taking Avinza. Additionally, patients must not use prescription or non-prescription medications containing alcohol while on Avinza therapy. Cylert and generic pemoline products: Audience: Neuropsychiatric healthcare professionals, Pediatricians, Pharmacists and consumers. Posted 10 24 2005 FDA has concluded that the overall risk or liver toxicity from Cylert and generic pemoline products outweighs the benefits of this drug. In May 2005, Abbott chose to stop sales and marketing of Cylert in the U.S. All generic companies have also.
From the Department of Molecular and Cellular Biochemistry, College of Medicine, Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, KY 40536; and Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, M5S 3H2, Canada Received, July 20, 2004, and in revised form, October 20, 2004 Published, MCP Papers in Press, October 21, 2004, DOI 10.1074 mcp.M400094-MCP200.
Program's inpatient center at Avon Park and includes follow-up visits to patients and their families after discharge. the family inpatients, nurses will direction of a provide services 14-county area alcoholic treatnearly half its to for Lumex.
Hepatocarcinogenicity of CPA was proposed by Roberts et al. 10 ; , who found that administration of CPA to male rats significantly reduced the basal level of apoptosis. Such an effect would prevent the removal of spontaneously DNAdamaged, potentially initiated cells 10 ; . Unfortunately, female rats were not investigated in this study and thus it is unclear whether even at elevated levels of DNA damage suppression of apoptosis by CPA occurs. In the present study investigations with primary rat hepatocytes of both sexes were done and the following aspects were experimentally addressed: i ; comparative measurement of the apoptotic activities of CPA in hepatocytes of male and female rats; ii ; investigations of the effects of the HST inhibitor dehydroepiandrosterone DHEA ; on CPA-induced apoptosis and CPA-induced genotoxicity; iii ; comparison of the potency of CPA in inducing apoptosis with that of chlormadinone acetate CMA ; and megestrol acetate MGA ; , two structural analogues of CPA. Rat liver cells were obtained from 810-week-old male and female Wistar rats 150200 g body wt ; . Isolation of hepatocytes was done according to the two step collagenase perfusion technique of Seglen 11 ; . Briefly, the rats were anaesthetized with an i.p. injection of pentobarbital sodium Nembutal; WDT, Hannover, Germany ; and their livers were perfused in situ for 10 min with Ca2 - and Mg2 -free Hanks' balanced salt solution HBSS ; supplemented with 10 mM HEPES and 0.5 mM EGTA, followed by collagenase digestion solution HBSS supplemented with 10 mM HEPES, 5 mM CaCl2 and 0.05% collagenase Type IV; Sigma, Deisenhofen, Germany ; for 10 min. After the collagenase digestion the hepatocytes were dispersed in ice-cold William's E medium WEM ; and filtered through a sterile gauze. The cell suspension was washed three times with cold WEM centrifugation at 50 g for 2 min ; to remove cell debris and non-parenchymal liver cells. The final cell pellet was resuspended in complete WEM William's E medium, 10% fetal calf serum, 2 mM L-glutamine, 0.1 mg streptomycin ml and 100 U penicillin ml ; . The viability was 75% as determined by Trypan Blue exclusion. For the analysis of apoptotic cells, hepatocytes were plated at a density of 8 104 cells cm2 onto rat tail collagencoated 6 mm dishes in 5 ml complete WEM supplemented with 107 M insulin. After 1.5 h the medium was changed to remove unattached cells. Twenty-four hours after initiating the hepatocyte cultures fresh medium with the test compound was added. As a positive control the growth inhibitory cytokine transforming growth factor-1 TGF-1 ; , a well-known inducer of apoptosis in rat hepatocytes, was used 12 ; . A further 24 h later all cultures were changed into serum-free conditions with the test compounds and exposure continued for 24 or 48 has been reported that serum-free conditions increase the sensitivity of hepatocytes to the effects of apoptosis-inducing agents 13 ; . In experiments where the influence of DHEA on CPA-induced apoptosis was investigated, DHEA was added 30 min before treatment with CPA started and co-exposure continued until the end of treatment as described above. After 2185.
Do not stop taking megestrol without talking to your doctor and melphalan.
Cancerbackup is a registered charity providing information on all aspects of cancer, and emotional support for people affected by cancer and their families. Cancerbackup's policy is to provide up-to-date, accurate information on cancer and its treatments, in line with accepted national and international guidelines and scientific evidence, or based upon a consensus of expert views. the content of Cancerbackup's publications is independent of any sponsorship. We make every effort to ensure that the information we provide is accurate but it should not be relied upon to reflect the current state of medical research, which is constantly changing. If you are concerned about your health, you should consult your doctor. Cancerbackup cannot accept liability for any loss or damage resulting from any inaccuracy in this information or third party information such as information on websites to which we link. Cancerbackup 2007, MeGestrOL aCetate MeGaCe ; . all rights reserved. no part of this publication may be reproduced or transmitted, in any form or by any means, including photocopying, recording or any information storage and retrieval system, without permission in writing from Cancerbackup. note: purchasers of the Cancerbackup Factfile 2007 may photocopy its contents for one year. Cancerbackup, 3 bath place, rivington street, London eC2a 3Jr. Charity registration no. 1019719. a company limited by guarantee. registered in england and Wales. Company no. 2803321. registered office as above.
Drug Name ELSPAR INJ 10000UNT Asparaginase ; EMCYT CAP 140MG Estramustine Phosphate Sodium ; ERBITUX INJ 100MG Cetuximab ; FARESTON TAB 60MG Toremifene Citrate ; FASLODEX INJ 125MG Fulvestrant ; FASLODEX INJ 250MG Fulvestrant ; FEMARA TAB 2.5MG Letrozole ; flutamide cap 125 mg GLEEVEC TAB 100MG Imatinib Mesylate ; GLEEVEC TAB 400MG Imatinib Mesylate ; HEXALEN CAP 50MG Altretamine ; hydroxyurea cap 500 mg INTRON-A INJ 10MU PEN Interferon Alfa-2B ; INTRON-A INJ 18MU Interferon Alfa-2B ; INTRON-A INJ 25MU Interferon Alfa-2B ; INTRON-A INJ 3MU PEN Interferon Alfa-2B ; INTRON-A INJ 5MU PEN Interferon Alfa-2B ; INTRON-A KIT 10MU ML Interferon Alfa-2B ; IRESSA TAB 250MG Gefitinib ; LEUKERAN TAB 2MG Chlorambucil ; leuprolide acetate inj 5 mg ml leuprolide acetate inj kit 5 mg ml leuprolide acetate inj kit 5 mg ml LUPR DEP-PED INJ 11.25MG Leuprolide Acetate ; LUPR DEP-PED INJ 15MG Leuprolide Acetate ; LUPR DEP-PED INJ 7.5MG Leuprolide Acetate ; LUPRON DEPOT INJ 11.25MG Leuprolide Acetate 3 Month LUPRON DEPOT INJ 22.5MG Leuprolide Acetate 3 Month LUPRON DEPOT INJ 3.75MG Leuprolide Acetate ; LUPRON DEPOT INJ 30MG Leuprolide Acetate 4 Month LUPRON DEPOT INJ 7.5MG Leuprolide Acetate ; LYSODREN TAB 500MG Mitotane ; MATULANE CAP 50MG Procarbazine HCl ; megestrol acetate susp 40 mg ml megestrol acetate tab 20 mg megestrol acetate tab 40 mg mercaptopurine tab 50 mg methotrexate sodium for inj 1 gm methotrexate sodium inj 25 mg ml methotrexate sodium tab 2.5 mg base equiv ; MYLERAN TAB 2MG Busulfan ; NEXAVAR TAB 200MG Sorafenib Tosylate ; NILANDRON TAB 150MG Nilutamide ; NIPENT INJ 10MG Pentostatin ; ONCASPAR INJ 750 ML Pegaspargase ; PLENAXIS INJ 100MG Abarelix ; PROLEUKIN INJ 22MU Aldesleukin ; SPRYCEL TAB 20MG Dasatinib ; SPRYCEL TAB 50MG Dasatinib ; SPRYCEL TAB 70MG Dasatinib and memantine.
ENROLLEE ACKNOWLEDGEMENT I understand that CHOICES Health Services Program does not cover all health care services that I may need. I understand that the services covered by the program are limited to the services described in this handbook. Payment for health care services that are not included in the CHOICES program is my responsibility. I also agree that if CHOICES makes a payment for services that are eligible for payment by another source, I authorize CHOICES to be reimbursed for their payment amount. My signature below means I have read and understand the information in this Enrollee Handbook. Enrollee Signature Enrollee Name Date Signed.
Fisher B, Anderson S, Wickerham DL, DeCillis A, Dimitrov N, Mamounas E, Wolmark N, Pugh R, Atkins JN, Meyers FJ, Abramson N, Wolter J, Bornstein RS, Levy L, Romond EH, Caggiano V, Grimaldi M, Jochimsen P & Deckers P 1997 Increased intensification and total dose of cyclophosphamide in a doxorubicincyclophosphamide regimen for the treatment of primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-22. Journal of Clinical Oncology 15 18581869. French Adjuvant Study Group 2001 ; . Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for nodepositive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 Randomized Trial. Journal of Clinical Oncology 19 602611. Fumoleau P, Kerbrat P, Romestaing P, Fargect P, Bremond A, Namer M, Schraub S, Goudier MJ, Mihura J, Mannier A, Clavere P, Serin D, Seffert P, Pourney C, Facchini T, Jacguin JP, Sztermer JF, Datchary J, Ramos R & Luporsi E 2003 Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10year follow-up results of the French Adjuvant Study Group 01 Trial. Journal of Clinical Oncology 21 298305. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ & Pater JL 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New England Journal of Medicine 349 17931802. Gnant M, Jakesz R, Mlineritsch B, Luschin-Ebengreuth G, Schmid M, Menzel C, Kubista E, Samonigg H, Hausmaninger H, the ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria 2004 Zoledronic acid effectively counteracts cancer treatment induced bone loss CTIBL ; on premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen -- bone density subprotocol results of a randomised multicenter trial ABCSG-12 ; . Breast Cancer Research and Treatment 88 Suppl 1 ; S8. Henderson IC, Berry DA & Demetri GD 2003 Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. Journal of Clinical Oncology 21 976983. Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A & Morris C 2002 Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Journal of Clinical Oncology 20 33963403. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY & Tobias JS 2005 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 21312139. Jakesz R, Kaufmann M, Gnant M, Jonat W, Mittleboek M, Greil R, Tausch C, Hilfrich J, Kwasny W, Samonigg H, on behalf of the ABCSG 2004 Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Research and Treatment 88 Suppl 1 ; S7. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL & Massimini G 2000 Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. Journal of Clinical Oncology 18 13991411. Klijn JG, Blamey RW, Boccardo F, Tominaga T & Duchateau L 2001 Combined tamoxifen and luteinizing hormone-releasing hormone LHRH ; agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. Journal of Clinical Oncology 19 343353. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H & Slamon DJ 2003 Quantitative association between HER-2 neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. Journal of the National Cancer Institute 95 142153. Kurokawa H & Arteaga CL 2003 ErbB HER ; receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clinical Cancer Research 9 Suppl ; 511515. Mamounas EP, Bryant J, Lembersky BC, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DC, Yothers G, Soran A & Wolmark N 2003 Paclitaxel T ; following doxorubicin cyclophosphamide AC ; as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proceedings of the American Society of Clinical Oncology 22 4 Abstract 12 ; . Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla J-P, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A & Vogel C for the Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for nodepositive breast cancer. New England Journal of Medicine 352 23022313 and meperidine.
Bellmunt J, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453 Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996; 14: 2000 Rutquist LE, Mattson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1995; 85: 1398 McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. Br Med J 1995; 311: 977 Anker G, Lnning PE, Ueland PM, Refsum H, Lien EA. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen. Int J Cancer 1995; 60: 365 Mooren MJ, Wouters MGAJ, Blom HJ, Schellekens LA, Eskes TKAB, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Investig 1994; 24: 733 Arnesen E, Refsum H, Bnaa KH, Ueland PM, Frde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704 Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395 Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230 Jones AL, Powles TJ, Law M, Tidy A, Easton E, Coombes RC, et al. Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. J Clin Oncol 1992; 10: 154752. Lundgren S, Helle SI, Lnning PE. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clin Cancer Res 1996; 2: 151521. Kvinnsland S, Lnning PE, Dahl O. Treatment of breast carcinoma with aminoglutethimide. Acta Radiol Oncol 1984; 23: 421 Johannessen DC, Engan T, Di Salle E, Zurlo MG, Paolini J, Ornati G, et al. Endocrine and clinical effects of exemstane PNV 15921 ; , a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997; 3: 1101.
Beled hormone was obtained with the enzymatic iodination, with much greater immunoreactivity and stability than after chloramine-t, besides being quite suitable for the measurement of low plasma insulin levels and mephenytoin.
Under the legislation of the data protection act 1998, i agree to allow the data to be used by the smoking advice service and other government departments for analysis purposes.
Megestrol cost
Such as those from companies like Xilinx8, Cadence9 and Mentor10 ; that provide integrated design environments where both software and hardware, and the mapping of software onto the hardware, can be specified. The area is intensively evolving. An interesting research project in this category is Metropolis11 which has the aim to support design from specification to implementation on hardware and software platforms. Two important parts of Metropolis are its methodology and meta-model tools are also available ; . The meta-model serves the purpose to allow different models of computation to be defined. The meta-model allows behaviors to be defined using the basic capabilities of actions, constraints, and their refinements. Quantity constraints enable the specification of performance and cost constraints such as time and power more information on Metropolis is available in the Hybrid systems tool survey, [Carloni et al., 2004] and meprobamate.
Two months later, full recovery of the patient's adrenal gland axis was documented with another 1-g cortrosyn stimulation test baseline serum cortisol level of 11 g and maximal cortisol level of 22 g minutes later ; , consistent with adrenal gland suppression during prior megestrol therapy.
Responsive to GABA knock-in mutations ; . In these mice the sedative actions of benzodiazepines are abolished but the anxiolytic, anticonvulsant and hypnotic ones remain Rudolph et al, 1999; Tobler et al, 2001 ; . al, al, Subsequent mutation of two remaining subtypes has shown that the anxiolytic effect is lost if the a2 but not the a3 subtype is mutated Low et al, 2000 ; . The localisaal, tion of the a2 subtype in the limbic system supports the role of this circuit in anxiety. This growing evidence for the specificity of benzodiazepine actions being mediated via receptor subtypes is leading to the search for subtype-selective drugs such as a2 or agonists as non-sedating anxiolytics and a5 inverse agonists which act mainly in the hippocampus ; as memory enhancers Lingford-Hughes et al, 2001 ; . al and mercaptopurine.
A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 1995: 75: 2132-8. Bisagni G, Cocconi G, Scaglione F et al. Letrozole. a new oral non steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Ann Oncol 1996; 7: 99-102. TominagaT, Ohashi Y, Abe R et al. Phase II trial of letrozole a novel oral nonsteroidal aromatase inhibitor ; in postmenopausal patients with advanced or recurrent breast cancer. Eur J Cancer 1995: 31A Suppl 5 ; : S81 Abstr ; . Dowsett M, Jones A, Johnston SRD et al. In vivo measurement of aromatase inhibition by letrozole CGS 20267 ; in post menopausal patients with advanced breast cancer. Clin Cancer Res 1995; 1: 1511-5. Ingle JN, Johnson PA, Suman VJ et al. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer 1997; 80: 218-24. Dombernowsky P, Smith I. Falkson G et al. Letrozole Femara E ; , a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose-effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453-61 Marty M, Gershanovich M, Campos D et al. Letrozole, a new potent, selective aromatase inhibitor Al ; superior to aminoglutethimide AG ; in postmenopausal women with advanced breast cancer ABC ; previously treated with anti-estrogens. Proc Soc Clin Oncol 1997; 16: Abstr 544 ; . Possinger K, Gershanovich M, Campos D et al for the Letrozole International Trial Group AR BC3 ; . Letrozole Femara ; , a new potent, selective aromatase inhibitor Al ; . Superior to another Al, aminoglutethimide AG ; , in postmenopausal women with advanced breast cancer ABC ; , after relapse or progression on previous anti-estrogen therapy. Eur J Cancer 1997; 43 Suppl 8 ; : Abstr 643. UICC - Manual of Adult and Paediatric Medical Oncology. In Monfardini S, Brunner K, Crowther D et al. eds ; : Evaluation of the Cancer Patient and the Response to Treatment. Berlin: Springer 1987; 22-38. George SL. The required size and length of a phase III clinical trial. In Buyse ME, Staquet MJ, Sylvester RJ eds ; : Cancer Clinical Trials: Methods and Practice, Chapter 18. Oxford: Oxford Medical Publications 1988. Howell A, Macintosh J, Jones M et al. The definition of the no change category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988; 24: 1567-72. Robertson JFR, Williams MR.Todd J et al. Factors predicting the response of patients with advanced breast cancer to endocrine Megace ; therapy. Eur J Cancer Clin Oncol 1989; 25: 469-75. Robertson JFR, Lee D. Static disease no change ; is an important remission criteria in patients treated with the aromatase inhibitor anastrozole. Proc Soc Clin Oncol 1997; 16: Abstr 528. Robustelli della Cuna G, Pannuti F, Martoni A et al. Aminoglutethimide in advanced breast cancer: Prospective, randomised comparison of two dose levels. Anticancer Res 1993: 13: 2367-72. Bonneterre J, Coppens H, Mauriac L et al. Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomised trial comparing 500 mg and I g per day. Eur J Clin Oncol 1985; 21: 1153-8. Harris A, Cantwell B, Carmichael J et al. Phase II study of low dose aminoglutethimide 250 mg day plus hydrocortisone in advanced breast cancer. Eur J Cancer Clin Oncol 1989; 25: 1105-11. Willemse P, Van des Ploeg E, Sleijfer D et al. A randomised comparison of megestrol acetate MA ; and medroxyprogesterone acetate MPA ; in patients with advanced breast cancer. Eur J Cancer 1990; 26: 337-43. Buzdar AU, Smith R, Vogel C et al. For the Multi-Institutional Trialist Collaborative Study Group. Fadrozole H O CGS 16949A ; versus megestrol acetate in postmenopausal patients with metastatic breast carcinoma. Results of two randomized double blind controlled multi-institutional trials. Cancer 1996; 77 12 ; : 2503-13. Gale KE. Andersen JW. Tormey DC et al. Hormonal treatment for metastatic breast cancer: An Eastern Cooperative Oncology Group phase III trial comparing aminoglutethimide to tamoxifen. Cancer 1994; 73 2 ; : 354-61. Muss HB. Well HB, Paschold EH. Megestrol acetate versus tamoxifen in advanced breast cancer five-year analysis -- a phase III trial of the Piedmont Oncology Association. J Clin Oncol 1985: 12: 40-2. Demers LM. Effects of Fadrozole CGS 16949A ; and letrozole CGS 20267 ; on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat 1994: 30: 95-102. Geisler J, King N, Dowsett M et al. Influence of anastrozole Arimidex K . a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996; 74: 1286-91. Bergh J, Bonneterre J, Illiger HJ et al. for the Vorozole Study Group. Vorozole Rivizor ; versus aminoglutethimide AG ; in the treatment of postmenopausal breast cancer relapsing after tamoxifen. Proc Soc Clin Oncol 1997; 16. Abstr 543. Jonat W, Howell A, Blomqvist C et al randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole Arimidex ; with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996; 32A: 404-12. Buzdar A, Jones S, Vogel C et al. A phase III Trial comparing anastrozole 1 and 10 milligrams ; , a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 1997, 79: 730-9. Buzdar A, Jonat W, Howell A et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. J Clin Oncol 1966; 14: 2000-11 Buzdar A, Jonat W, Howell A et al. on behalf of the Arimidex International Study Group, Houston, TX, Kiel, Germany. Manchester, UK, Wilmington, DE, Macclesfield, UK. Significant improved survival with Arimidex * anastrozole ; versus megestrol acetate in postmenopausal advanced breast cancer: Updated results of two randomised trials Proc Soc Clin Oncol 1997; 16: Abstr 545. Gross P, Wine E, Tannock I et al. Vorozole versus Megace K in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen. Proc Soc Clin Oncol 1997; 16: Abstr 542. Abrams JS, Cirrincione C, Aisner J et al. A phase III dose response trial of megestrol acetate MA ; in metastatic breast cancer M BC ; . Proc Soc Clin Oncol 1992; 11 Abstr 50. Hoffken K, Chacon R, Dombernowsky P et al. Fadrozole hydrochloride CGS 16949A ; , a double-blind dose-finding study in postmenopausal patients with advanced breast cancer. Ann Oncol 1992; 3 Suppl 5 ; : 76 Abstr ; . Lee K, Macaulay VM, Nicholls JE et al. An in vivo model of intratumoral aromatase using aromatase-transfected MCF7 human breast cancer cells. Int J Cancer 1995; 62: 297-302 and megestrol.
14.TopinkaJ., Andrae.U., Schwarz, L.R., Werner.S., Sram.RJ. and Wolff.T. 1993 ; Persistence and accumulation of DNA adducts induced by the synthetic steroid cyproterone acetate in rat liver in vivo. Proc. 23rdAnnual Meeting of the EEMS, Barcelona, 27 September-2 October, pp. 2-38. 15.Williams, G.M. 1977 ; Detection of chemical carcinogens by unscheduled DNA synthesis in rat liver primary cell cultures. Cancer Res., 37, 1845-1851. 16.Glantz, S.A. 1992 ; Primer of Biostatistics. McGraw-Hill, New York. 17.Tatematsu, M., Hasegawa, R., Imaida.K., Tsuda, H. and Ito, N. 1983 ; Survey of various chemicals for initiating and promoting activities in a short-term in vivo system based on generation of hyperplastic liver nodules in rats. Carcinogenesis, 4, 381-386. 18.0gawa, K., Solt, D. and Farber.E. 1980 ; Phenotypic diversity as an early property of putative preneoplastic hepatocyte population in liver carcinogenesis. Cancer Res., 40, 725-733. 19 tenberg, A.M., FischbeinJ.W., Kim, H., HankerJ.S., Wasserkrug.H.L. and Seligman.A.M. 1969 ; Histochemical and ultrastructural demonstration of y-glutamyl-transpeptidase activity. J. Hislochem. Cytochem., 17, 517526. 2O mpbell, H.A., Pitot, H.C, van Potter.R. and Laishes, B.A. 1982 ; Application of quantitative stereology to the evaluation of enzyme-altered foci in rat liver. Cancer Res., 42, 465-472. 21.AshbyJ., Lefevre.P.A., Burlinson.B. and Beije.B. 1986 ; Potent mitogenic activity of 4-acetylaminofluorene to the rat liver. Mutat. Res., Ill, 271-279. 22.TopinkaJ, Binkova, B., ZhuJ-l.K., Andrae.U., Neumann.I., Schwarz.L.R., Wemer.S. and Wolff, T. 1995 ; DNA damaging activity of the cyproterone acetate analogues chlormadinone acetate and megestrol acetate in rat liver. Carcinogenesis, 16, 1483-1487. 23. Watanabe.S., Yamasaky.S., Tanae A., Ibi J., Ad Hoc Commitee on Androcur Users and Honna, T. 1994 ; Three cases of hepatocellular carcinoma among cyproterone users. Lancet, 344, 1567-1568 24. Rtldiger, T., BeckmannJ. and Queisser.W. 1995 ; Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyl-oestradiol. Lancet, 345, 452-453. 25, Rabe, T., Feldmann.K, Grunwald.K. and Runnebaum.B. 1994 ; Liver tumors in women on oral contraceptives. Lancet, 344, 1568-1569. 26. Schwarz, L.R., Werner, S., Topinka J , Andrae.U., Neumann.I. and Wolff, T. 1995 ; The liver as origin and target of reactive intermediates exemplified by the progesterone derivative, cyproterone acetate. In Snyder.R. et al. eds ; , Biological Reactive Intermediate. V. Basic Mechanistic Research in Toxicology and Human Risk Assessment. Plenum Press, New York in press ; . 27, Kerdar, R.S., Baumann, A., Brudny-Kloppel.M, Biere.H., Blode.H. and Kuhnz, W. 1995 ; Identification of 3a-hydroxy-cyproterone acetate as a metabolite of cyproterone acetate in the bile of female rats and the potential of this and other already known or putative metabolites to form DNA adducts in vitro. Carcinogenesis, 16, 1835-1841. Received on July 25, 1995: revised on November 15, 1995; accepted on November 22, 1995 and meropenem.
Saquinavir for, 1301 stavudine for, 12861287 sulfonamide hypersensitivity in, 1116 suramin use in, 1069 tenofovir for, 12901291 toxoplasmosis in, 1051 trimethoprim-sulfamethoxazole hypersensitivity in, 1119 tuberculosis in, 1215 tuberculosis prophylaxis in, 1216 vaccines against, 1309t viral action in, 1275 viral life cycle in, 12741275, 1274f viral load in, 1275 viral structure in, 12731274, 1274f wasting in megestrol acetate for, 1561 testosterone for, 1581 zalcitabine for, 12871288 zidovudine for, 12831285 Human leukocyte antigens HLAs ; in diabetes mellitus, 1621 polymorphisms in, 106t, 110 soluble, 1421 Human megakaryocyte growth and development factor rHuMGDF ; , 1442 Human papillomavirus HPV ; antiviral agents for, 1691 imiquimod for, 1267, 1696 interferons for, 1264 Human proinsulin HPI ; , 1627 HUMATIN paromomycin ; , 10631064 HUMATROPE somatotropin ; , 1495 HUMIRA adalimimab ; , 1419 HUMULIN insulin ; , 1624 Huntingtin, 541 Huntington's disease, 540541 antipsychotics for, 484485 basal ganglia in, 540, 540f depression in, treatment of, 541 energy metabolism in, 529 environmental triggers in, 528 genetics of, 528, 540541 limbic system in, 318 movement disorder of, treatment of, 541 as prototypical neurodegenerative disorder, 527 selective vulnerability in, 527, 540541 treatment of, 527, 541, 544 HYALUTIN hydroxyprogesterone caproate ; , 1561 HYCAMTIN topotecan ; , 1356 Hydantoin s ; interaction with sulfonamides, 1116 HYDELTRA-T. B. A. prednisolone tebutate ; , 1602t Hydralazine, 860861 adverse effects of, 861, 881 for congestive heart failure, 881 with isosorbide dinitrate, 877, 881 for hypertension, 860862 and lupus syndrome, 861, 881 metabolism of, 861 pharmacological effects of, 860861 therapeutic uses of, 861862.
G37. HAND CARD #34 ; SInce we last interviewed you on BASELINE DATE, have you taken any drugs or treatments for wasting such as those listed on this card? READ IF NEEDED: Megace megestrol acetate ; Marinol dronabinol ; Testosterone or other anabolic steriod Growth Hormone Serostim, HGH ; Oral liquid food supplements Ensure, or others ; Parenteral nutrition TPN, PPN, feeding by vein or central line ; Thalidomide Synovir and mesna.
The member ID submitted on the claim was not valid based on the patient's date of birth. The provider must resubmit the claim with a valid member ID and melphalan.
|
Copyright © 2007 by Buying.fizwig.com Inc.
